IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.
Follow IDXX
IDEXX Laboratories, Inc. (IDXX) Altman Z-score
IDEXX Laboratories, Inc.'s Altman Z-score for fiscal 2025 is 24.09, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 24.09 | 7.35 |
| FY2024 | 16.75 | (3.18) |
| FY2023 | 19.92 | 6.27 |
| FY2022 | 13.66 | (9.96) |
| FY2021 | 23.62 | 4.46 |
| FY2020 | 19.16 | 7.51 |
| FY2019 | 11.65 | 1.92 |
| FY2018 | 9.74 | 2.50 |
| FY2017 | 7.24 | 1.05 |
| FY2016 | 6.19 | 1.56 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.08 | — | 0.09 | |
| Retained earnings / total assets | 1.91 | — | 2.67 | |
| EBIT / total assets | 0.41 | — | 1.34 | |
| Market value of equity / total liabilities | 31.17 | — | 18.70 | |
| Sales / total assets | 1.28 | — | 1.28 | |
| Altman Z-score | Safe zone | 24.09 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 10.43 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NTRA Natera, Inc. compare | 26.8× |
| IDXX IDEXX Laboratories, Inc. | 24.1× |
| MTD Mettler-Toledo International, Inc. compare | 10.2× |
| WAT Waters Corporation compare | 9.6× |
| A Agilent Technologies, Inc. compare | 5.5× |
| ILMN Illumina, Inc. compare | 4.4× |
| DGX Quest Diagnostics Incorporated compare | 3.1× |
| LH Labcorp Holdings Inc. compare | 3.0× |
| IQV IQVIA Holdings Inc. compare | 2.0× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets
More on IDXX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement